Combination therapy with leuprolide acetate and tamoxifen in refractory ovarian cancer

International Journal of Gynecological Cancer

Volumn 6, Issue 1, 1996, Pages 15-19

  Lopez, A ^a   Tessadrelli, A ^a   Kudelka, A P ^a   Edwards, C L ^a   Freedman, R S ^a   Hord, M ^a   Kavanagh, J J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

hormonal therapy; leuprolide acetate; ovarian carcinoma; platinum resistance; tamoxifen; Taxol

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LEUPRORELIN; PLATINUM; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEADACHE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OVARY CANCER; PRIORITY JOURNAL;

EID: 0029918998     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1996.06010015.x     Document Type: Article

References (26)

1. Wingo PA, Tong T, Bolden S, et al. Cancer statistics, 1995. Cancer 1995; 45: 8-30.
2. Howell SB, Solomon Z, Markman M, et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987; 5: 1607-12.
3. Rubin SC, Hoskins WJ, Hakes TB, et al. Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors. Am J Obstet Gynecol 1988; 159: 1094-8.
4. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-9.
5. Holt JA, Caputo TA, Kelly KM, et al. Estrogen and progesterone binding in cytosols of ovarian adenocarcinomas. Obstet Gynecol 1979; 53: 50-8.
6. Galli MC, DeGiovanni C, Nicoletti G, et al. The occurence of multiple steroid hormone receptors in disease-free and neoplastic human ovary. Cancer 1981; 47: 1297-302.
7. Emons G, Pahwa GS, Brack C, et al. Gonadotrophin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 1989; 25: 215-21.
8. Grönroos M, Kangas L, Mäenpää J, et al. Steroid receptors and response of ovarian cancer to hormones in vitro. Br J Obstet Gynaecol 1984; 91: 472-8.
9. Lazo JS, Schwartz PE, MacLusky NJ, et al. Antiproliferative actions of tamoxifen to human ovarian carcinomas in vitro. Cancer Res 1984; 44: 2266-71.
10. Runge HM, Teufel G, Neulen J, et al. In vitro responsiveness of ovarian epithelial carcinomas to endocrine therapy. Cancer Chemother Pharmacol 1986; 16: 58-63.
11. Langdon SP, Hawkes MM, Lawrie SS, et al. Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. Br J Cancer 1990; 62: 213-6.
12. Thompson MA, Adelson MD, Kaufman LM. Lupron retards proliferation of ovarian epithelial tumor cells cultured in serum-free medium. J Clin Endocrinol Metab 1991; 72: 1036-41.
13. Peterson CM, Jolles CJ, Carrell DT, et al. GnRH agonist therapy in human ovarian epithelial carcinoma (OVCAR-3) heterotransplanted in the nude mouse is characterized by latency and transience. Gynecol Oncol 1994; 52: 26-30.
14. Shirey DR, Kavanagh JJ, Gershenson DM, et al. Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol 1985; 66: 575-8.
15. Campbell JJ, Rome RM, Quinn MA, et al. Tamoxifen for recurrent progressive epithelial ovarian tumors. Med Pediatr Oncol 1985; 13: 150-1 (Abstract).
16. Hatch KD, Beecham JB, Blessing JA, et al. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. Cancer 1991; 68: 269-71.
17. Ahlgren JD, Ellison NM, Gottlieb RJ, et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993; 11: 1957-68.
18. Kavanagh JJ, Roberts W, Townsend P, et al. Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol 1989; 7: 115-8.
19. Fromm G-L, Freedman RS, Fritsche HA, et al. Sequentially administered ethinyl estradiol and medroxyprogesterone acetate in the treatment of refractory epithelial ovarian carcinoma in patients with positive estrogen receptors. Cancer 1991; 68: 1885-9.
20. Dickson RB, Huff KK, Spencer EM, et al. Induction of epidermal growth factor-related polypeptides by 17 β-estradiol in MCF-7 human breast cancer cells. Endocrinol 1985; 118: 138-42.
21. Huff KK, Knabbe C, Lindsey R, et al. Multihormonal regulation of insulin-like growth factor-I-related protein in MCF-7 human breast cancer cells. Molec Endocrinol 1988; 2: 200-8.
22. Krywicki RF, Figueroa JA, Jackson JG, et al. Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen. Eur J Cancer 1993; 29A: 2015-9.
23. Lind MJ, Cantwell BMJ, Millward MJ, et al. A phase II trial of goserilin (Zoladex) in relapsed epithelial ovarian cancer. Br J Cancer 1992; 65: 621-3.
24. Parmar H, Rustin G, Lightman SL, et al. Response to D-Trp-6-luteinising hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer. Br Med J 1988; 296: 1229.
25. Emons G, Ortmann O, Becker M, et al. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 1993; 53: 5439-46.
26. Kavanagh JJ, Kudelka AP, Edwards CL, et al. A randomized crossover trial of parenteral hydroxyurea vs high dose taxol in cisplatin/carboplatin resistant epithelial ovarian cancer. Proc Am Soc Clin Oncol 1993; 12: 259 (Abstract).